Endocrine, metabolic & immune disorders drug targets最新文献

{"title":"Contribution of Type 2 Diabetes Susceptible Gene GCKR Polymorphisms Rs780094 and Rs1260326 to Gestational Diabetes Mellitus: A Meta-Analysis.","authors":"Yuke Zhang, Kuangyi Wang, Chenxi Ji, Yansi Lin, Zitong Liu, Jing Chen, Feifei Zheng, Xiaoqin Yang, Yi Sun","doi":"10.2174/0118715303313654241101042033","DOIUrl":"https://doi.org/10.2174/0118715303313654241101042033","url":null,"abstract":"<p><strong>Background: </strong>There is still no conclusive understanding of whether the glucokinase regulator (GCKR) gene rs780094 and rs1260326 polymorphisms predispose to gestational diabetes mellitus (GDM).</p><p><strong>Objective: </strong>This systematic review and meta-analysis aimed to determine the effect of the GCKR polymorphisms on GDM susceptibility.</p><p><strong>Methods: </strong>Seven literature databases were searched (from inception to February 17, 2024) to locate relevant studies included in further meta-analysis. Odds ratio (OR) and 95% confidence intervals (CI) in the pooled population were estimated to assess the effects of the variant allele on GDM risk.</p><p><strong>Results: </strong>For the rs780094 polymorphism, 13 datasets with 3443 GDM cases and 5930 nondiabetic controls were included. The pooled estimates in the allele model (OR: 1.19, 95% CI: 1.07~1.32), homozygote model (OR: 1.27, 95% CI: 1.10~1.47), dominant model (OR: 1.16, 95% CI: 1.03~1.31), and recessive model (OR: 1.31, 95% CI: 1.09~1.57) suggested that the C allele carriers were prone to GDM. For the rs1260326 polymorphism, five datasets with 1495 cases and 2678 controls were integrated. The statistically significant effect of the C allele was evident in the allele model (OR: 1.12, 95% CI: 1.01~1.24) and the homozygote model (OR: 1.26, 95% CI: 1.03~1.54).</p><p><strong>Conclusion: </strong>This meta-analysis suggested that the C allele of the rs780094 and rs1260326 polymorphisms in the GCKR gene are significantly associated with increased risk of GDM.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma Hepatic Transaminases and Incidence of Metabolic Syndrome Before Midlife in Military Adults: A CHIEF Cohort Study.","authors":"Fang-Chen Liu, Kai-Wen Chen, Kun-Zhe Tsai, Chen-Chih Chu, Yen-Chen Lin, Yun-Chen Chang, Gen-Min Lin","doi":"10.2174/0118715303326392241022050205","DOIUrl":"https://doi.org/10.2174/0118715303326392241022050205","url":null,"abstract":"<p><strong>Background: </strong>Plasma AST and ALT may reflect the nonalcoholic fatty liver disease (NAFLD) severity and have been associated with the risk of MetS in middle- or old-aged individuals.</p><p><strong>Aims: </strong>This study aimed to examine the associations of plasma hepatic aspartate and alanine transaminases (AST and ALT) levels with incident metabolic syndrome (MetS) in young adults, which have not been verified before.</p><p><strong>Objective: </strong>The goal of this study was to identify the association between plasma hepatic transaminases and the incidence of new-onset MetS among young adults.</p><p><strong>Methods: </strong>There were 2,804 military men and women, with ages of 18-39 years, free of baseline MetS and any viral hepatitis in Taiwan in 2014. Incident MetS were followed in the annual military health examinations from baseline till the end of 2020. The definition of MetS was made using the criteria of the International Diabetes Federation. Plasma concentrations of AST and ALT were checked at baseline. A Multivariable Cox regression model with adjustments for sex, age, each component of MetS, body mass index, substance use status, and physical activity at baseline was performed to determine the associations. Subgroup analyses were performed according to sex and each MetS component.</p><p><strong>Results: </strong>During a median follow-up of 5.8 years, 644 incident MetS (23.0%) developed. ALT and AST levels (each 10 U/L increase) were respectively associated with 5% and 11% increased risk of incidence of MetS (hazard ratios (HRs) and 95% confidence intervals (CIs): 1.05 (1.01-1.09) and 1.11 (1.04-1.19), respectively). In subgroup analyses, the risk of incidence of MetS with ALT and AST levels respectively increased 75% and 114% in women (HRs: 1.75 (1.07-2.87) and 2.14 (1.35-3.41), respectively), and 7% and 14% in those free of central obesity (HRs: 1.07 (1.02-1.11) and 1.14 (1.06-1.23), respectively) which were higher than their counterparts (p-values for interaction by sex: 0.06 and 0.001, respectively; and by central obesity: 0.04 and 0.07, respectively).</p><p><strong>Conclusion: </strong>Plasma hepatic transaminase levels were positively associated with incident MetS among young adults. The individual role of central obesity and sex on the association of ALT and AST with incident MetS should be further clarified.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lingguizhugan Decoction in the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.","authors":"Yifan Lu, Lijuan Nie, Xinyi Yang, Ziming Zhao, Yuxiao Wang, Qibiao Wu, Xiqiao Zhou","doi":"10.2174/0118715303323071241022053842","DOIUrl":"https://doi.org/10.2174/0118715303323071241022053842","url":null,"abstract":"<p><strong>Objective: </strong>This study systematically evaluated the efficacy and safety of Ling Gui Zhu Gan Decoction for treating non-alcoholic fatty liver disease.</p><p><strong>Methods: </strong>Registered under CRD42024501460 on the PROSPERO platform, we searched eight major databases, including Web of Science, PubMed, Cochrane, Embase, China National Knowledge Infrastructure, Wanfang database, Chinese Scientific Journals Database, and Chinese Biomedicine Database, from inception to December 2023 for randomized controlled trials on Ling Gui Zhu Gan Decoction in non-alcoholic fatty liver disease treatment. We extracted data on total efficiency, TC, TG, ALT, AST, GGT, and HOMA-IR, analyzing results with RevMan 5.4 software.</p><p><strong>Results: </strong>Twelve studies met the inclusion criteria, encompassing 970 cases. Ling Gui Zhu Gan Decoction, alone or combined with standard therapy, significantly improved non-alcoholic fatty liver disease outcomes, regardless of treatment duration. Only one study reported adverse events, including bloating, diarrhea, nausea, vomiting, and rash.</p><p><strong>Conclusion: </strong>Ling Gui Zhu Gan Decoction appears to be an effective and safe option for non-alcoholic fatty liver disease treatment. However, due to limited studies and methodological weakness, further rigorous randomized controlled trials are necessary for conclusive results.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Network Pharmacology Unveils Multi-Systemic Intervention of Panax notoginseng in Osteoporosis via Key Genes and Signaling Pathways.","authors":"Qiyue Wang, Xiaoping Wang, Kezhou Wu, Weiwei Wu, Zhantu Wei, Weili Feng","doi":"10.2174/0118715303335018241107084224","DOIUrl":"https://doi.org/10.2174/0118715303335018241107084224","url":null,"abstract":"<p><strong>Background: </strong>Panax notoginseng (Burk.) F. H. Chen (PN) is a traditional Chinese medicine that has been applied to prevent and treat osteoporosis. The mechanism of PN for osteoporosis remained a mystery.</p><p><strong>Objective: </strong>The objective was to reveal the therapeutic effect and illuminate the possible mechanism of PN for osteoporosis.</p><p><strong>Methods: </strong>The Traditional Chinese Medicine Database and Analysis Platform was searched to screen the potent ingredients of the PN and to analyze the potential therapeutic targets for osteoporosis. We excavated four disease databases to collect osteoporosis-related genes. After integrating the gene expression profile of osteoporosis and the chemical-protein data of PN, a protein-protein interaction network was constructed to demonstrate the interactions among the gene products. GO function, KEGG pathway, and docking analyses were executed.</p><p><strong>Results: </strong>Network pharmacology obtained 31 active ingredients and 134 targets for the treatment of osteoporosis. The key components were beta-elemene, quercetin, methyl palmitate, oleic acid, and hexanal. The results of GO and KEGG analyses showed that Panax notoginseng was beneficial for osteoporosis by influencing the main pathways including AGE-RAGE signaling pathway in diabetic complications, TNF signaling pathway, IL-17 signaling pathway, p53 signaling pathway, NF-kappa B signaling pathway, PI3K-Akt signaling pathway, MAPK signaling pathway, FoxO signaling pathway, and Wnt signaling pathway, modulating inflammation, metabolism, cell proliferation, cell survival, growth and angiogenesis. Panax notoginseng intervened in osteoporosis through multi-components, multi-targets, and multi-pathways.</p><p><strong>Conclusion: </strong>This study illustrates the mechanism of Panax notoginseng for osteoporosis, providing broader insights for novel research and developments of the Panax species for osteoporosis.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare of Gaucher's Disease Complication of Splenic Multiple Gaucheroma.","authors":"Nursima Çukadar, İrem Erdoğan Veziroğlu, Canan Sehit Kara, Okkes Ibrahim Karahan, Tutkun Talih, Fahri Bayram","doi":"10.2174/0118715303325860241023063241","DOIUrl":"10.2174/0118715303325860241023063241","url":null,"abstract":"<p><strong>Background: </strong>Gaucheromas, pseudotumors composed of Gaucher cells, are rare complications of Gaucher's Disease (GD). They are usually seen in patients receiving enzyme replacement. Surgery is generally not recommended for these benign masses in treatment management. Most patients treated with Enzyme Replacement Therapy (ERT) show organ enlargement and improvement in laboratory values. In our case, no change in the size of the lesions was observed despite 4 years of standard dose ERT.</p><p><strong>Case presentation: </strong>A 27-year-old female, not having a known chronic disease and occasionally consulting doctors due to bone pain, weakness, and fatigue, visited the emergency department with the complaint of a nosebleed four years ago. The patient was found to have hepatosplenomegaly in physical examination and was referred to the hematology clinic because of pancytopenia. According to the physical examination and laboratory results, the desired leukocyte glucocerebrosidase level was 0.4 micromol/lt/hour (normal range > 2.5). Homozygous mutations of p.L483P and L483P were observed in genetic tests. Based on these results, the patient was diagnosed with GD. Although the patient received regular weekly treatment for 4 years, no significant change was observed in the spleen size. The patient was admitted to the hospital in April 2022 with complaints of abdominal fullness and indigestion. Her quality of life was deteriorating due to massive splenomegaly. A splenectomy was performed on the patient. In our case, splenic gaucheroma, a rare complication of Gaucher's disease, was found to be present.</p><p><strong>Conclusion: </strong>These masses, which are a rare complication of GD, have started to be better recognized by radiologists and clinicians thanks to the case series shared, and it is clear that there is a need for standardization and further research in this field. With an increase in the number of cases and experiences in this field, there will inevitably be different and new developments in follow-up and treatment approaches.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Berberine Improves Glucose and Lipid Metabolism in Obese Mice through the Reduction of IRE1/GSK-3β Axis-Mediated Inflammation.","authors":"Lina Ding, Jingjing Xia, Hua Wang, Junyi Qian, Xiaodan Jin, Yang Yang, Jing Xia, Wenbin Shang, Ming Chen","doi":"10.2174/0118715303319434241113161606","DOIUrl":"https://doi.org/10.2174/0118715303319434241113161606","url":null,"abstract":"<p><strong>Introduction: </strong>Berberine (BBR) has the characteristics of repressing hyperglycemia, obesity, and inflammation, as well as improving insulin resistance. However, the underlying mechanism remains to be fully understood. This study explores whether BBR regulates inositol requiring enzyme 1 (IRE1)/glycogen synthase kinase 3 beta (GSK-3β) axis to resist obesity-associated inflammation, thereby improving glucolipid metabolism disorders.</p><p><strong>Method: </strong>Mice were fed a high-fat diet and administrated with BBR, followed by measurement of weight change, biochemical indicators, as well as glucose and insulin tolerance. Insulin-resistant 3T3-L1 adipocyte models were established, and the model cells were treated with BBR and IRE1 inhibitors. Cell viability was detected by cell counting kit-8 assay. Inflammatory factor secretion and glucose consumption were measured via specific kits. Oil red O staining was used to observe lipid droplet formation, and protein expressions in the IRE1/GSK-3β axis were determined via Western blot.</p><p><strong>Results: </strong>BBR reduced weight, insulin resistance, levels of triglyceride, total cholesterol, free fatty acid, high-density lipoprotein, and low-density lipoprotein but improved glucose tolerance in obese mice. BBR and IRE1 inhibitors demonstrated no cytotoxicity. BBR and IRE1 inhibitors diminished secretion of tumor necrosis factor-alpha, interleukin-6, and monocyte chemoattractant protein 1, lipid droplet formation, and values of p-IRE1/IRE1 and p-GSK-3β/GSK-3β, but elevated glucose consumption in insulin-resistant adipocytes.</p><p><strong>Conclusion: </strong>BBR improves glucose and lipid metabolism in obese mice through the reduction of IRE1/GSK-3β axis-mediated inflammation, showing the great potential of BBR in reversing insulin resistance in obesity.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving Renal Protection in Chronic Kidney Disease Associated with Type 2 Diabetes: The Role of Finerenone.","authors":"Pringgodigdo Nugroho","doi":"10.2174/0118715303350851241021105850","DOIUrl":"https://doi.org/10.2174/0118715303350851241021105850","url":null,"abstract":"<p><p>Chronic kidney disease (CKD) is a major complication of type 2 diabetes mellitus (T2D), which often leads to diabetic kidney disease (DKD). Traditional therapies, including renin- angiotensin-aldosterone system inhibitors and sodium-glucose cotransporter-2 inhibitors, are effective in slowing CKD progression. However, these approaches are insufficient to comprehensively inhibit mineralocorticoid receptor (MR) overactivation in the kidneys, which remains a significant driver of inflammation, fibrosis, and oxidative stress. These pathological processes accelerate kidney damage and cardiovascular complications. Finerenone-a nonsteroidal mineralocorticoid receptor antagonist-represents a new frontier in renal protection. Unlike steroidal mineralocorticoid antagonists (MRAs), finerenone offers a more selective MR blockade, reducing kidney inflammation and fibrosis without significantly raising serum potassium levels. Landmark trials have demonstrated the ability of finerenone to significantly reduce kidney and cardiovascular events in patients with T2D and CKD. Clinical evidence has highlighted finerenone as an effective option for slowing DKD progression while maintaining a favorable safety profile. Based on these findings, recent guidelines have incorporated finerenone as a recommended therapy for patients with T2D and CKD, emphasizing its role in reducing both renal and cardiovascular risks. This review provides a comprehensive overview of the available data to offer a deeper understanding of the potential of finerenone to transform CKD management for T2D patients.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142961059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significance of Serum Magnesium in Parathyroid Hormone Level in Patients with Chronic Kidney Disease.","authors":"Jiali Wang, Yongda Lin, Xiutian Chen, Hong-Yan Li, Wenzhuang Tang, Tianbiao Zhou","doi":"10.2174/0118715303311081241022042321","DOIUrl":"https://doi.org/10.2174/0118715303311081241022042321","url":null,"abstract":"<p><strong>Introduction: </strong>In chronic kidney disease (CKD) patients, elevated parathyroid hormone (PTH) is linked to cardiovascular mortality and morbidity. Levels of PTH are influenced by serum phosphate (P) and calcium (Ca), but little is known about the impact of magnesium (Mg) on PTH. Hence, this study investigated the relationship between PTH and Mg in peritoneal dialysis (PD) patients and non-dialysis patients from three hospitals in China.</p><p><strong>Material and methods: </strong>This cross-sectional study included 446 chronic kidney disease stage 5 (CKD5) patients from three hospitals in southern China. PTH was naturally transformed to Ln_PTH for analysis. The chi-square test, Pearson correlation analysis, hierarchical regression analysis, and t-test were used to explore the relationships between Ln_PTH and gender, diabetes history, Mg, P, Ca, albumin (Alb), red blood cells (RBC), hemoglobin (Hb), white blood cells (WBC), and platelet (Plt).</p><p><strong>Results: </strong>Patients with diabetes mellitus (DM) had lower levels of Ln_PTH in PD (P<0.05) and non-dialysis (P>0.05) patients. Ln_PTH levels were negatively associated with Mg and Ca but positively associated with P and Alb in PD patients (all P<0.05). Ln_PTH levels were negatively associated with age but positively associated with P in non-dialysis patients (all P<0.05).</p><p><strong>Conclusion: </strong>This study demonstrates the negative effect of Mg and diabetes on Ln_PTH levels in CKD5 patients.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142961070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do SGLT2 Inhibitors Protect the Kidneys? An Alternative Explanation.","authors":"Jacob Ilany","doi":"10.2174/0118715303355221241021050443","DOIUrl":"https://doi.org/10.2174/0118715303355221241021050443","url":null,"abstract":"<p><p>SGLT2 inhibitors are a family of drugs that were developed to treat diabetes mellitus. In randomized controlled trials, SGLT2 inhibitors seem to prevent kidney deterioration in patients with nephropathies, both diabetic and non-diabetic. However, in contrast to biochemical/physiological results (proteinuria and serum creatinine levels) that improve in all studies, the clinical results (all-cause mortality, cardiovascular death, need for dialysis, or renal transplant) do not consistently improve. In this article, the author would like to suggest that SGLT2 inhibitors do not, in fact, prevent the progression of renal diseases but rather alter laboratory results. This study will present a theory that gives an alternative explanation for the findings in the studies that would explain the above discrepancy between biochemical/physiological and clinical results. In general, the author claims that SGLT2 inhibitors change the kinetics of renal creatinine and microalbumin excretion but do not prevent parenchymal adverse changes in kidneys. This causes a dissociation between renal function markers (such as serum creatinine level and urinary protein) and the real kidney function. Thus, the clinical renal prognosis does not improve despite seemingly better laboratory results.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142961034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case Report of Recurrent Primary Pituitary Abscess: Challenges in Diagnosis and Treatment.","authors":"Dilan Ozaydin, Ahmet Numan Demir, Tufan Agah Kartum, Ender Vergili, Pinar Kadioglu, Necmettin Tanriover","doi":"10.2174/0118715303338996241021094336","DOIUrl":"https://doi.org/10.2174/0118715303338996241021094336","url":null,"abstract":"<p><strong>Background: </strong>Primary pituitary abscess is a rare disease with no specific symptoms for pituitary abscess alone. A preoperative diagnosis is quite challenging due to unclear imaging findings.</p><p><strong>Case presentation: </strong>We report the case of a patient with a pituitary lesion who presented with hypopituitarism, diabetes insipidus, and visual field defect and was misdiagnosed as a possible cystic pituitary adenoma. Endoscopic endonasal transsphenoidal surgery (ETSS) was performed, and surprisingly, only pus was found, and complete resection of the lesion was achieved. Coagulase-negative staphylococci were detected in the culture, and appropriate antibiotic therapy was administered for six weeks. Diabetes insipidus and hypopituitarism did not improve. One year later, the abscess recurred, and a second operation with complete resection was performed.</p><p><strong>Conclusion: </strong>Knowledge of primary pituitary abscess, a rare infectious disease, is essential for early detection and successful treatment. Most patients have a chronic and silent prediagnostic course with symptoms that are not specific to pituitary abscess alone. The primary treatment option is EETS, followed by long-term, relevant antibiotics. The disease can be resistant and recur despite appropriate treatment, especially in patients with risk factors. Therefore, long-term follow-up of patients is essential.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142961011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}